New Appointment to the Corporate Structure of Egenix, Inc.

MILLBROOK, N.Y., June 27, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce that Paul H. Schwartz, DVM, CVA has joined Egenix, Inc. to head up a new subsidiary that will focus on veterinary medicine.

We are honored to have Dr. Schwartz aboard, and are confident that he will contribute to the further success of Egenix.

Dr. Paul Schwartz is a Doctor of Veterinary Medicine with extensive practices throughout New York. He is accomplished in the care of small animals and equines. In his practice, he has remained on the forefront with the development of new procedures and technologies in veterinary science.

In addition to developing and managing his Veterinary Centers, Dr. Schwartz is experienced in bringing new technologies to market and running several for profit enterprises.  He is currently the President of Equine Nutriceuticals, LLC, in Bloomsbury, NJ, and previously was President of the Veterinary Medical Division of Drug Delivery Systems Inc, NYC, NY. 

Dr. Schwartz has a BS in Statistics and a Doctor of Veterinary Medicine from the University of Florida Gainesville, FL.  His post Baccalaureate Training includes Advanced Orthopedics Canine/Equine (OSU), and Advanced Ultrasound Imaging/Echocardiography. In addition, he holds certification in Tibial Plateau Leveling (TPLO/Slocum Inst.) and Veterinary Acupuncture (IVAS). 

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, and neurological disorders, i.e. autism. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. For more information visit www.egenixinc.com

SOURCE Egenix, Inc.